Skip to main content
Clinton F. Stewart, PharmD
Clinton F. Stewart, PharmD


BSPh – Auburn University
PharmD – University of Tennessee, Memphis, TN

Honors & Awards

  • 2012 Research Advisor Award, University of Tennessee Health Science Center, College of Graduate Health Sciences
  • 2009 Fellow, American Association of Pharmaceutical Scientists
  • 1994 Fellow, American College of Clinical Pharmacists

Research Interests

  • CNS and tumor penetration of novel agents used to treat pediatric CNS tumors in relevant mouse models
  • Pharmacokinetic and pharmacodynamic modeling and simulation to derive safe and effective anti-cancer drug regimens for infants and young children with brain tumors
  • Novel methods to optimize drug exposure in children with cancer (eg, pharmacokinetically guided dosing)

Improving Drug Therapy for Children with Brain Tumors

Selected Publications

See full list of publications

Robinson GW, Rudneva VA, Buchhalter I, Billups CA, Waszak SM, Smith KS, Bowers DC, Bendel A, Fisher PG, Partap S, Crawford JR, Hassall T, Indelicato DJ, Boop F, Klimo P, Sabin ND, Patay Z, Merchant TE, Stewart CF, Orr BA, Korbel JO, Jones DTW, Sharma T, Lichter P, Kool M, Korshunov A, Pfister SM, Gilbertson RJ, Sanders RP, Onar-Thomas A, Ellison DW, Gajjar A, Northcott PA. Risk-adapted therapy for young children with medulloblastoma (SJYC07): therapeutic and molecular outcomes from a multicentre, phase 2 trial. Lancet Oncol 19:768-784, 2018. (PMCID: PMC6078206)

Broniscer A, Jia S, Mandrell B, Hamideh D, Huang J, Onar-Thomas A, Gajjar A, Raimondi SC, Tatevossian RG, Stewart CF. Phase I trial, pharmacokinetics, and pharmacodynamics of dasatinib combined with crizotinib in children with recurrent or progressive high-grade and diffuse intrinsic pontine glioma. Pediatr Blood Cancer Mar 7, 2018. doi: 10.1002/pbc.27035. [Epub ahead of print] PMID: 29512900

Nimmervoll B, Boulos N, Bianski B, Dapper J, DeCuypere M, Shelat A, Terranova S, Gilbertson H, Gajjar A, Patel Y, Freeman BB 3rd, Onar-Thomas A, Stewart CF, Rousell MF, Guy RK, Merchant TE, Calabrese C, Wright K, Gilbertson RJ. Establishing a Preclinical Multidisciplinary Board for Brain Tumors. Clinical Cancer Research 24:1654-1666, 2018. PMCID: PMC5884708 PMID: 29301833

Robinson GW, Rudneva VA, Buchhalter I, Billups CA, Waszak SM, Smith KS, Bowers DC, Bendel A, Fisher PG, Partap S, Crawford JR, Hassall T, Indelicato DJ, Boop F, Klimo P, Sabin ND, Patay Z, Merchant TE, Stewart CF, Orr BA, Korbel JO, Jones DTW, Sharma T, Lichter P, Kool M, Korshunov A, Pfister SM, Gilbertson RJ, Sanders RP, Onar-Thomas A, Ellison DW, Gajjar A, Northcott PA. Risk-adapted therapy for young children with medulloblastoma (SJYC07): therapeutic and molecular outcomes from a multicenter phase 2 trial. Lancet Oncology 19:768-784, 2018. (PMC: in progress) PMID: 29778738.

Zhong B, Maharaj A, Davis A, Roussel MF, Stewart CF. Development and validation of a sensitive LC MS/MS method for the measurement of the checkpoint kinase 1 inhibitor prexasertib and its application in a cerebral microdialysis study. J Pharmaceutical Biomedical Analysis 156:97-103, 2018. (PMC: in progress) PMID: 29698863

Banerjee A, Jakacki RI, Onar-Thomas A, Wu S, Nicolaides T, Young Poussaint T, Fangusaro J, Phillips J, Perry A, Turner D, Prados M, Packer RJ, Qaddoumi I, Gururangan S, Pollack IF, Goldman S, Doyle LA, Stewart CF, Boyett JM, Kun LE, Fouladi M. A phase I trial of the MEK inhibitor selumetinib AZD6244 in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium PBTC study. Neuro-Oncol 19:1135-1144, 2017. PMCID: PMC5570236 PMID: 28339824

Brennan RC, Qaddoumi I, Mao S, Wu J, Billups CA, Stewart CF, Hoehn ME, Rodriguez-Galindo C, Wilson MW. Ocular Salvage and Vision Preservation Using a Topotecan-Based Regimen for Advanced Intraocular Retinoblastoma. J Clin Oncol 35:72-77, 2017. PMCID: PMC5455691 PMID: 28034080

Kala A, Patel YT, Davis A, Stewart CF. Development and validation of LC-MS/MS methods for the measurement of ribociclib, a CDK4/6 inhibitor, in mouse plasma and Ringer's solution and its application to a cerebral microdialysis study. J Chromatogr B Analyt Technol Biomed Life Sci 1057:110-117, 2017. PMCID: PMC5512115 PMID: 28521250

Karol SE, Yang W, Smith C, Cheng C, Stewart CF, Baker SD, Sandlund JT, Rubnitz JE, Bishop MW, Pappo AS, Jeha S, Pui CH, Relling MV. Palmar-plantar erythrodysesthesia syndrome following treatment with high-dose methotrexate or high-dose cytarabine. Cancer 123:3602-3608, 2017. PMCID: PMC5589497 PMID: 28493546

Leong R, Zhao H, Reaman G, Liu Q, Wang Y, Stewart CF, Burckart G. Bridging Adult Experience to Pediatrics in Oncology Drug Development. J Clin Pharmacol 57 Suppl 10:S129-S135, 2017. PMCID: in progress PMID: 28921643

Millisor VE, Roberts JK, Sun Y, Tang L, Daryani VM, Gregornik D, Cross SJ, Ward D, Pauley JL, Molinelli A, Brennan RC, Stewart CF. Derivation of new equations to estimate glomerular filtration rate in pediatric oncology patients. Pediatr Nephrol 2017. PMCID: PMC5712286 PMID: 28573537

Moj D, Britz H, Burhenne J, Stewart CF, Egerer G, Haefeli WE, Lehr T. A physiologically based pharmacokinetic and pharmacodynamic PBPK/PD model of the histone deacetylase HDAC inhibitor vorinostat for pediatric and adult patients and its application for dose specification. Cancer Chemother Pharmacol 80:1013-1026, 2017. PMCID: in progress PMID: 28988277

Navid F, Santana VM, Neel M, McCarville MB, Shulkin BL, Wu J, Billups CA, Mao S, Daryani VM, Stewart CF, Kunkel M, Smith W, Ward D, Pappo AS, Bahrami A, Loeb DM, Reikes Willert J, Rao BN, Daw NC. A phase II trial evaluating the feasibility of adding bevacizumab to standard osteosarcoma therapy. Int J Cancer 141:1469-1477, 2017. PMCID: PMC5812455 PMID: 28631382

Patel YT, Daryani VM, Patel P, Zhou D, Fangusaro J, Carlile DJ, Martin PD, Aarons L, Stewart CF. Population pharmacokinetics of selumetinib and its metabolite n-desmethyl-selumetinib in adult patients with advanced solid tumors and children with low-grade gliomas. CPT Pharmacometrics Syst Pharmacol 6:305-314, 2017. PMCID: PMC5445231 PMID: 28326681

Stewart CF, Robinson GW. Development of molecularly targeted therapies to treat pediatric malignancies. Clin Pharmacol Ther 102:752-753, 2017. PMCID: PMC5656826 PMID: 28836264

Daryani VM, Patel YT, Tagen M, Turner DC, Carcaboso AM, Atkinson JM, Gajjar A, Gilbertson RJ, Wright KD, Stewart CF. Translational Pharmacokinetic-Pharmacodynamic Modeling and Simulation: Optimizing 5-Fluorouracil Dosing in Children with Pediatric Ependymoma. CPT Pharmacometrics Syst Pharmacol 5:211-221, 2016. PMCID: PMC4834132 PMID: 27104090

Edelmann MN, Daryani VM, Bishop MW, Liu W, Brinkman TM, Stewart CF, Mulrooney DA, Kimberg C, Ness KK, Cheung YT, Srivastava DK, Robison LL, Hudson MM, and Krull KR. Neurocognitive and Patient-Reported Outcomes in Adult Survivors of Childhood Osteosarcoma. JAMA Oncol 2:201-8, 2016. PMCID: PMC4752424 PMID: 26583357

Jacus MO, Daryani VM, Harstead KE, Patel YT, Throm SL, Stewart CF. Pharmacokinetic Properties of Anticancer Agents for the Treatment of Central Nervous System Tumors: Update of the Literature. Clin Pharmacokinet 55:297-311, 2016. PMCID: PMC4761278 PMID: 26293618

Morfouace M, Nimmervoll B, Boulos N, Patel YT, Shelat A, Freeman BB 3rd, Robinson GW, Wright K, Gajjar A, Stewart CF, Gilbertson RJ, Roussel MF. Preclinical studies of 5-fluoro-2'-deoxycytidine and tetrahydrouridine in pediatric brain tumors. J Neurooncol 126:225-34, 2016. PMCID: PMC4718940 PMID: 26518542

Navid F, Herzog CE, Sandoval J, Daryani VM, Stewart CF, Gattuso J, Mandrell B, Phipps S, Chemaitilly W, Sykes A, Davidoff AM, Shulkin BL, Bahrami A, Furman WL, Mao S, Wu J, Schiff D, Rao B, Pappo A. Feasibility of Pegylated Interferon in Children and Young Adults with Resected High-Risk Melanoma. Pediatr Blood Cancer 7:1207-13, 2016. PMCID: PMC4877209 PMID: 27038395

Patel YT, Jacus MO, Davis AD, Boulos N, Turner DC, Vuppala PK, Freeman BB 3rd, Gilbertson RJ, Stewart CF. Simvastatin Hydroxy Acid Fails to Attain Sufficient Central Nervous System Tumor Exposure to Achieve a Cytotoxic Effect: Results of a Preclinical Cerebral Microdialysis Study. Drug Metab Dispos 44:591-4, 2016. PMCID: PMC4810761 PMID: 26802130

Phoenix TN, Patmore DM, Boop S, Boulos N, Jacus MO, Patel YT, Roussel MF, Finkelstein D, Goumnerova L, Perreault S, Wadhwa E, Cho YJ, Stewart CF, Gilbertson RJ. Medulloblastoma Genotype Dictates Blood Brain Barrier Phenotype. Cancer Cell 29: 508-22, 2016. PMCID: PMC4829447 PMID: 27050100

Roberts JK, Birg AV, Lin T, Daryani VM, Panetta JC, Broniscer A, Robinson GW, Gajjar AJ, Stewart CF. Population Pharmacokinetics of Oral Topotecan in Infants and Very Young Children with Brain Tumors Demonstrates a Role of ABCG2 rs4148157 on the Absorption Rate Constant. Drug Metab Dispos 7:1116-22, 2016. PMCID: PMC4931885 PMID: 27052877

Salloum R, Hummel TR, Kumar SS, Dorris K, Li S, Lin T, Daryani VM, Stewart CF, Miles L, Poussaint TY, Stevenson C, Goldman S, Dhall G, Packer R, Fisher P, Pollack IF, Fouladi M, Boyett J, Drissi R. A molecular biology and phase II study of imetelstat GRN163L in children with recurrent or refractory central nervous system malignancies: a pediatric brain tumor consortium study. J Neurooncol 3:443-51, 2016. PMCID: PMC5288808 PMID: 27350411

Wetmore C, Daryani VM, Billups CA, Boyett JM, Leary S, Tanos R, Goldsmith KC, Stewart CF, Blaney SM, Gajjar A. Phase II evaluation of sunitinib in the treatment of recurrent or refractory high-grade glioma or ependymoma in children: a children's Oncology Group Study ACNS1021. Cancer Med 7:1416-24, 2016. PMCID: PMC4944867 PMID: 27109549

DeWire M, Fouladi M, Turner DC, Wetmore C, Hawkins C, Jacobs C, Yuan Y, Liu D, Goldman S, Fisher P, Rytting M, Bouffet E, Kahkoo Y, Hwang E, Foreman N, Stewart CF, Gilbert MR, Gilbertson R, Gajjar A. An open-label, two-stage, Phase II study of bevacizumab and lapatinib in children with recurrent or refractory ependymoma: A Collaborative Ependymoma Network Study CERN. J Neurooncol 123:85-91, 2015. PMCID: PMC4992988 PMID: 25859842

Guo J, Glass JO, McCarville MB, Shulkin BL, Daryani VM, Stewart CF, Wu J, Mao S, Dwek JR, Fayad LM, Madewell JE, Navid F, Daw NC, Reddick WE. Assessing vascular effects of adding bevacizumab to neoadjuvant chemotherapy in osteosarcoma using DCE-MRI. Br J Cancer 113:1282-8, 2015. PMCID: PMC4815789 PMID: 26461056

Hoffman LM, Fouladi M, Olson J, Daryani VM, Stewart CF, Wetmore C, Kocak M, Onar-Thomas A, Wagner L, Gururangan S, Packer RJ, Blaney SM, Gajjar A, Kun LE, Boyett JM, Gilbertson RJ. Phase I trial of weekly MK-0752 in children with refractory central nervous system malignancies: a pediatric brain tumor consortium study. Childs Nervous System 31:1283-1289, 2015. PMCID: PMC4681692 PMID: 25930724

Jacus MO, Rahija R, Davis A, Throm SL, Stewart CF. An observational evaluation of mice during cerebral microdialysis procedures used in pediatric brain tumor research. J Am Assoc Lab Anim Sci 54: 304-10, 2015. PMCID: PMC4460944 PMID: 26045457

Kieran MW, Chi S, Goldman S, Onar-Thomas A, Poussaint TY, Vajapeyam S, Fahey F, Wu S, Turner DC, Stewart CF, Moses M, Packer RJ, Jakacki R, Banerjee A, Boyett JM, Fouladi M, Kun L. A phase I trial and PK study of cediranib AZD2171, an orally bioavailable pan-VEGFR inhibitor, in children with recurrent or refractory primary CNS tumors. Childs Nerv Syst 31:1433-45, 2015. PMCID: PMC4561207 PMID: 26188774

Show More

Morfouace M, Cheepala SB, Jackson S, Fukuda Y, Patel YT, Soghra F, Kawauchi D, Shelat AA, Stewart CF, Sorrentino B, Schuetz JD, Roussel MF. ABCG2 transporter expression impacts Group3 Medulloblastoma response to chemotherapy. Cancer Res 75: 3879-3889, 2015. PMCID: PMC4573843 PMID: 26199091

Nikanjam M, Stewart CF, Takimoto CH, Synold TW, Beaty O, Fouladi M, Capparelli EV. Population pharmacokinetic analysis of oxaliplatin in adults and children identifies important covariates for dosing. Cancer Chemotherap Pharmacol 75:495-503, 2015. PMCID: PMC4344382 PMID: 25557868

Packer RJ, Rood BR, Turner DC, Stewart CF, Fisher M, Smith C, Young-Pouissant T, Goldman S, Lulla R, Banerjee A, Pollack I, Kun L, Boyett JM, Onar-Thomas A, Wu S, Fouladi M. Phase I and pharmacokinetic trial of PTC299 in pediatric patients with refractory or recurrent central nervous system tumors: a PBTC study. Journal of NeuroOncology 121:217-224, 2015. PMCID: PMC4330963 PMID: 25407389

Patel Y, Jacus M, Boulos N, Dapper J, David A, Vuppala P, Freeman III B, Mohankumar K, Throm S, Gilbertson R, Stewart CF. Preclinical examination of clofarabine in pediatric ependymoma: intratumoral concentrations insufficient to warrant further study. Cancer Chemotherap Pharmacol 75:897-906, 2015. PMID: PMC4420645 PMID: 25724157

Robinson GW, Orr BA, Wu G, Gururangan S, Lin T, Qaddoumi I, Packer R, Goldman S, Prados M, Desjardins A, Chintagumpala M, Takebe N, Kaste SC, Rusch M, Allen SJ, Onar-Thomas A, Stewart CF, Fouladi M, Boyett JM, Gilbertson RJ, Curran T, Ellison DW, Gajjar A. Vismodegib exerts targeted efficacy against recurrent SHH-subgroup medulloblastoma: results from phase II pediatric brain tumor consortium studies – PBTC-025B and PBTC-032. J Clin Oncol 33:2646-2654, 2015. PMCID: PMC4534527 PMID: 26169613

Scott JR, Zhou Y, Cheng C, Ward DA, Swanson HD, Molinelli AR, Stewart CF, Navid F, Jeha S, Relling MV, Crews KR. Comparable efficacy with varying dosages of glucarpidase in pediatric oncology patients. Pediatr Blood Cancer 62:1518-1522, 2015. PMCID: PMC4770903 PMID: 25631103

Vilgelm AE, Pawlikowski JS, Liu Y, Hawkins OE, Davis TA, Smith J, Weller KP, Horton LW, McClain CM, Ayers GD, Turner DC, Essaka DC, Stewart CF, Sosman JA, Kelley MC, Ecsedy JA, Johnston JN, Richmond A. Mdm2 and Aurora A inhibitors synergize to block melanoma growth by driving apoptosis and immune clearance of tumor cells. Cancer Research 75:181-93, 2015. PMCID: PMC4286469 PMID: 25398437

Wright KD, Panetta JC, Onar-Thomas A, Reddick WE, Patay Z, Qaddoumi I, Broniscer A, Robinson G, Boop FA, Klimo P, Ward D, Gajjar A, Stewart CF. Delayed methotrexate excretion in infants and young children with primary central nervous system tumors and postoperative fluid collections. Cancer Chemother Pharmacol 75:27-35, 2015. PMCID: PMC4282603 PMID: 25342291

Wright KD, Daryani VM, Turner DC, Onar-Thomas A, Boulos N, Orr BA, Gilbertson RJ, Stewart CF, Gajjar A. Phase I study of 5-fluorouracil in children and young adults with recurrent ependymoma. Neuro Oncol 17:1620-7, 2015. PMCID: PMC4633933 PMID: 26541630

Xu H, Robinson GW, Huang Jie, Lim JY-S, Zhang H, Bass JK, Broniscer A, Chintagumpala M, Bartels U, Gururangan S, Hassall T, Fisher M, Cohn R, Yamashita T, Teitz T, Zuo J, Onar-Thomas A, Gajjar A, Stewart CF, Yang JY. Common variants in ACYP2 influence susceptibility to cisplatin-induced hearing loss. Nature Genetics 47:263-266, 2015. PMCID: PMC4358157 PMID: 25665007

Brennan RC, Furman W, Mao S, Wu J, Turner DC, Stewart CF, Santana V, McGregor LM. Phase I dose escalation and pharmacokinetic study of oral gefitinib and irinotecan in children with refractory solid tumors. Cancer Chemotherap Pharmacol 74:1191-1198, 2014. PMCID: PMC4562671 PMID: 25257509

Gottardo NG, Hansford JR, McGlade JP, Alvaro F, Ashley DM, Bailey S, Baker DL, Bourdeaut F, Cho YJ, Clay M, Clifford SC, Cohn RJ, Cole CH, Dallas PB, Downie P, Doz F, Ellison DW, Endersby R, Fisher PG, Hassall T, Heath JA, Hil HL, Jones DT, Junckerstorff R, Kellie S, Kool M, Kotecha RS, Lichter P, Laughton SJ, Lee S, McCowage G, Northcott PA, Olson JM, Packer RJ, Packer RJ, Pfister SM, Pietsch T, Pizer B, Pomeroy SL, Remke M, Robinson GW, Rutkowski S, Schoep T, Schoep T, Shelat AA, Stewart CF, Sullivan M, Taylor MD, Wainwright B, Walwyn T, Weiss WA Williamson D, Gajjar A. Medulloblastoma Down Under 2013: a report from the third annual meeting of the International Medulloblastoma Working Group. Acta Neuropathol 127:189-201, 2014. PMCID: PMC3895219 PMID: 24264598

Gurney JG, Bass JK, Onar-Thomas A, Huang J, Chintagumpala M, Bouffet E, Hassall T, Gururangan S, Heath JA, Kellie S, Cohn R, Fisher MJ, Panadiker AP, Merchant TE, Srinivasan A, Wetmore C, Qaddoumi I, Stewart CF, Armstrong GT, Broniscer A, Gajjar. Evaluation of amifostine for protection for protection against cisplatin-induced serious hearing loss in children treated for average-risk or high-risk medulloblastoma. Neuro Oncol 16:848-55, 2014. PMCID: PMC4022215 PMID: 24414535

Jacus MO, Throm SL, Turner DC, Patel YT, Freeman BB 3rd, Morfouace M, Boulos N, Stewart CF. Deriving therapies for children with primary CNS tumors using pharmacokinetic modeling and simulation of cerebral microdialysis data. Eur J Pharm Sci 57:41-7, 2014. PMCID: PMC4004667 PMID: 24269626

Morfouace M, Shelat A, Jacus M, Freeman BB 3rd, Robinson S, Turner D, Zindy F, Wang Y-D, Finkelstein D, Bihannic L, Puget S, Ayrault O, Li X-N, Olson JM, Robinson GW, Guy RK, Stewart CF, Gajjar A, Roussel MF. Pemetrexed and gemcitabine as combination therapy for the treatment of group 3 medulloblastoma. Cancer Cell 25:516-29, 2014. PMCID: PMC3994669 PMID: 24684846

Roberts MS, Turner DC, Broniscer A, Stewart CF. Determination of crizotinib in human and mouse plasma by liquid chromatography electrospray ionization tandem mass spectrometry LC-ESI-MS/MS. J Chromatography B 960C:151-157, 2014. PMCID: PMC4062842 PMID: 24811158

Stewart CF, Tagen M, Schwartzberg LS, Blakely LJ, Tauer KW, Smiley LM. Phase I dosage finding and pharmacokinetic study of intravenous topotecan and oral erlotinib in adults with refractory solid tumors. Cancer Chemother Pharmacol 73:561-8, 2014. PMCID: PMC3965853 PMID: 24448640

Turner DC, Navid F, Daw NC, Mao S, Wu J, Santana VM, Neel M, Rao B, Willert JR, Loeb DM, Harstead KE, Throm SL, Freeman BB III, Stewart CF. Population pharmacokinetics of bevacizumab in children with osteosarcoma: implications for dosing. Clinical Cancer Research 20:1-10, 2014. PMCID: PMC4024352 PMID: 24637635

Zimmerman EI, Turner DC, Buaboonnam J, Hu S, Orwick S, Roberts MS, Janke LJ, Ramachandran A, Stewart CF, Inaba H, Baker SD. Crenolanib is active against models of drug-resistant FLT3-ITD-positive acute myeloid leukemia. Blood 122:33607-15, 2013. PMCID: PMC3837509 PMID: 24046014

Blaney SM, Tagen M, Onar-Thomas A, Berg SL, Gururangan S, Scorsone K, Su J, Goldman S, Kieran MW, Kun L, Boyett J, Stewart CF. A phase-1 pharmacokinetic optimal dosing study of intraventricular topotecan for children with neoplastic meningitis: A pediatric brain tumor consortium study. Pediatr Blood Cancer 60:627-632, 2013. PMCID: PMC3573253 PMID: 23002039

Broniscer A, Baker SD, Wetmore C, Pai Panadiker A, Huang J, Davidoff AM, Onar-Thomas A, Panetta JC, Chin TK, Merchant TE, Baker JN, Kaste SC, Gajjar A, Stewart CF. Phase I trial, pharmacokinetics, and pharmacodynamics of vandetanib and dasatinib in children with newly diagnosed diffuse intrinsic pontine glioma. Clinical Cancer Research 19: 3050-3058, 2013. PMCID: PMC3685168 PMID: 23536435

Cruz-Marcelo A, Rosner GL, Muller P, Stewart CF. Effect on prediction when modeling covariates in Bayesian nonparametric models. J Stat Theory and Practice 7:204-218, 2013. PMCID: PMC3656440 PMID: 23687472

Fouladi M, Stewart CF, Blaney SM, Onar-Thomas A, Schaiquevich P, Packer RJ, Gajjar A, Kun LE, Boyett JM, Gilbertson RJ. A molecular biology and Phase II trial of lapatinib in children with refractory CNS malignancies: A Pediatric Brain Tumor Consortium Study. J Neuro-Oncology 114:173-9, 2013. PMCID: PMC4246636 PMID: 23836190

Gajjar A, Stewart CF, Ellison DW, Kaste S, Kun LE, Packer RJ, Goldman S, Chintagumpala M, Wallace D, Takebe N, Boyett JM, Gilbertson RJ, Curran T. Phase I study of vismodegib in children with recurrent or refractory medulloblastoma: a pediatric brain tumor consortium study. Clin Cancer Res 19:6305-12, 2013. PMCID: PMC3856244 PMID: 24077351

MacDonald TJ, Vezina G, Stewart CF, Turner D, Pierson CR, Chen L, Pollack IF, Gajjar A, Kieran MW. Phase II study of cilengitide in the treatment of refractory or relapsed high-grade gliomas in children: A report from the Children’s Oncology Group. Neuro-Oncology 15:1438-44, 2013. PMCID: PMC3779033 PMID: 24014381

Roberts MS, Turner DC, Owens TS, Ramachandran A, Wetmore C, Throm SL, Stewart CF. Determination of crenolanib in human serum and cerebrospinal fluid by liquid-electrospray ionization-tandem mass spectrometry (LC-ESI-MS/MS). J Chrom B 292:1-5, 2013. PMCID: PMC3665945 PMID: 23644495

Turner DC, Tillmanns TD, Harstead KE, Throm SL, Stewart CF. Combination metronomic oral topotecan and pazopanib: a pharmacokinetic study in cancer patients with gynecologic cancer. Anticancer Research 33:3823-9, 2013. PMCID: PMC4386652 PMID: 24023315

Yang JJ, Lim JY-S, Huang J, Bass J, Wu J, Wang C, Fang J, Stewart E, Harstead EH, Shuyu E, Robinson GW, Evans WE, Pappo A, Zuo J, Relling MV, Onar-Thomas A, Gajjar A, Stewart CF. The Role of Inherited TPMT and COMT Genetic Variation in Cisplatin-induced Ototoxicity in Children with Cancer. Clinical Pharmacol Therap 94:252-9, 2013. PMCID: PMC3883563 PMID: 23820299

Last update: October 2018